Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL2007426 | 0.94 | NAPRT (0.53) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL10977701 | 0.94 | NAPRT (0.60) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL179840 | 0.94 | NAPRT (0.60) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL11125163 | 0.94 | NAPRT (0.60) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL767139 | 0.92 | NAPRT (0.50) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL5844201 | 0.91 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL4558243 | 0.91 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL9246176 | 0.91 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL10380397 | 0.91 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK | |
| Pyridine SCHEMBL5844202 | 0.91 | NAPRT (0.56) | NAPRTTSHRTDP1FFAR3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345164-B2 | Production method of 5′-acyloxynucleoside compound | AJINOMOTO CO., INC. (JP) | 2008-03-18 | — | — | US | disclosed |
| US-20040230053-A1 | Production method of 5'-acyloxynucleoside compound | AJINOMOTO CO., INC. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1471071-A1 | Production method of 5'-acyloxynucleoside compound | Ajinmoto Co., Inc. (JP) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040230053-A1 | Production method of 5'-acyloxynucleoside compound | ALKBH2, DUT, ALKBH1 | NAPRT 252/4885TSHR 3691/4885TDP1 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.